Reportlinker Adds Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities
NEW YORK, March 24 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities
This cutting edge & insightful report can be used to interpret & assess the potential of RNAi-based medicines. It provides opinions & market projections to:
- assess the commercial potential of RNAi-based therapies in all of the key therapeutic areas: cancer, CNS disorders, viral infectious diseases, ocular diseases, cardiovascular, metabolic and other conditions;
- identify key pharma & delivery specialists advancing RNAi-based therapeutics & diagnostics;
- gain an in-depth understanding of the technological & delivery issues which face companies developing RNAi-based therapies;
- evaluate the options available for chemically and structurally modifying RNAi silencing agents and delivering them to target tissues now & in the future;
- discover which companies are tackling efficacy and safety issues & are in a prime position to exploit new opportunities;
- analyze how the market will evolve over the next decade highlighting key trends, opportunities & challenges.
Chapter 1 RNA Interference & Delivery
Key Findings
Introduction
RNAi a Natural Phenomenon
Antisense technologies
RNAi silencing agents
RNA silencing pathways
microRNAs and antagomirs
miRNA gene silencing
Pros & Cons of RNAi Silencing Agents
RNAi R&D
High throughput in vitro screening
RNAi in vivo screening
RNAi diagnostic makers
RNAi Therapeutics
RNAi Diagnostics
RNAi Therapy - A Discovery Timeline
Major Scientific Challenges for the Development of RNAi-Based
Diagnostics & Therapies
Report Structure
Chapter 2 RNAi-Based Therapeutics: Pipeline Analysis
Key Points
Key Therapy Areas Covered by RNAi-Based Therapies
Product pipelines
RNAi for Diagnostics
RNAi Companies Analyzed in This Report
Chapter 3 RNAi-Based Therapies for Cancer
Key Findings
Introduction
RNAi delivery in cancer
RNAi-Based Therapies -siRNA
Case study: ALN-VSP (Alnylam Pharmaceuticals)
Case study: CALAA-01 (Calando Pharmaceuticals)
Case study: Dicer substrate RNA (Dicerna Pharmaceuticals)
Case study: Intratumoral siRNA (Genesis Research & Development
Corporation)
Case study: NPX delivery technology (Intradigm Corporation)
Case study: SNS-01 (Senesco Technologies)
Case study: Atu027 (Silence Therapeutics)
Case study: STP702 (Sirnaomics)
Case study: PLK SNALP (Tekmira Pharmaceutical Corporation)
RNAi-Based Therapies -shRNA
Case study: CEQ501 (Cequent Pharmaceuticals)
Alternative RNA Approaches to Develop Cancer Therapies
miRNA in Cancer
Case study: miRNAs (Mirna Therapeutics)
Case study: miRNAs (Regulus Therapeutics)
Case study: SPC2996 & EZN3042 (Santaris Pharma A/S/Enzon
Pharmaceuticals)
MiRNA-Based Diagnostics
mRNA Antagonists
Case study: LOR-2040 (Lorus Therapeutics)
Antisense
Case study: OGX-011 (Isis Pharmaceuticals/OncoGenex) &
LY2181308 (Isis Pharmaceuticals/Eli Lilly)
Case study: TF siRNA (siRNAsense A/S/Polyplus Transfection)
Conclusions
Our Opinion on RNAi-Based Therapies & Diagnostics for Cancer
Where the technology is now, its evolution, achievements and pitfalls
Competition
Potential future applications
Activity in the market, major players and winners
Chapter 4 RNAi-Based Therapies for CNS Disorders
Key Findings
Introduction
Neurodegenerative Diseases
Amyotrophic lateral sclerosis
Case study: SOD1 siRNA (RXi Therapeutics)
Case study: SOD1 shRNA (Oxford BioMedica)
Huntington's Disease
Case study: ALN-HTT (Alnylam Pharmaceuticals/Medtronic)
Case study: AVV-HTT (Targeted Genetics Corporation)
Parkinson's Disease
Case study: SNCA-siRNA (Alnylam Pharmaceuticals)
Case study: biotinylated siRNA (ArmaGen Technologies)
Other CNS conditions
Conclusions
Our Opinion on RNAi-Based Therapies for CNS disorders
Where the technology is now, its evolution, achievements and pitfalls
Competition
Potential future applications
Activity in the market, major players and winners
Chapter 5 RNAi-Based Therapies for Viral Infectious Diseases
Key Findings
Introduction
Respiratory Syncytial Virus
Case study: ALN-RSV01 (Alnylam Pharmaceuticals)
Hepatitis C
Case study: TT-033 (Oncolys BioPharma/Pfizer/Tacere Therapeutics)
Case study: miR-122 (Regulus Therapeutics)
Case study: SPC3649 (Santaris Pharma A/S)
Human Immunodeficiency Virus
Case study: rHIV7-shl-TAR-CCR5RZ (Benitec Ltd/City of Hope)
Pandemic Influenza
Bioterrorism
Other Infectious Diseases
Conclusions
Our Opinion on RNAi-Based Therapies for Viral Infectious Diseases
Where the technology is now, its evolution, achievements and pitfalls
Competition
Potential future applications
Activity in the market
Chapter 6 RNAi-Based Therapies for Ocular Diseases
Key Findings
Introduction
Age-Related Macular Degeneration
Case study: AGN-745 (Allergan/Sirna Therapeutics)
Case study: VEGF-A165b sparing siRNA & Bevasiranib (Opko Health)
Case study: PF-4523655 (Quark Pharmaceuticals/Pfizer)
Diabetic Retinopathy & Diabetic Macular Edema
Glaucoma
Conclusions
Our Opinion on RNAi-Based Therapies for Ocular Diseases
Where the technology is now, its evolution, achievements and pitfalls
Competition
Potential future applications
Activity in the market
Chapter 7 RNAi-Based Therapies for Cardiovascular, Metabolic & Other Conditions
Key Points
Introduction
RNAi-Based Therapeutics for Cardiovascular Diseases
Case study: miR-21 (Regulus Therapeutics)
Case Study: MHC miRNA inhibitors (MiRagen Therapeutics Inc)
RNAi-Based Therapeutics for Metabolic Disorders
Case Study: ApoB SNALP (Tekmira Pharmaceutical Corporation)
Case study: MDR-04227 (MDRNA)
Case Study: PCSK9 siRNA (Alnylam Pharmaceuticals)
Case study: ApoB rxRNA and GeRP delivery (RXi Therapeutics)
RNAi-Based Therapeutics in Other Therapeutic Areas
Case study: ALN-TTR siRNA (Alnylam Pharmaceuticals)
Case study: HSP47 siRNA (Nitto Denko Technical Corporation)
Case study: QPI-1002 (Silence Therapeutics/Quark Pharmaceuticals)
Conclusion
Our Opinion on RNAi-Based Therapies for Cardiovascular, Metabolic
& Other Diseases
Where the technology is now, its evolution, achievements and pitfalls
Competition
Potential future applications
Activity in the market, major players and winners
Chapter 8 Challenges & Opportunities for RNAi-Based Therapeutics & Diagnostics
Key Points
Introduction
Stability & Efficacy Issues for RNAi Research
Stability
Efficacy
Safety Issues for RNAi Research
Intellectual Property
Delivering RNAi-Based Therapies
Challenges
Opportunities
Chapter 9 The Future of RNAi-Based Therapeutics & Diagnostics: Market Trends
Key Points
Key RNAi Companies
Leading RNAi-Based Therapeutic Companies
Leading miRNA-Based Therapeutic Companies
Leading RNAi-Based Diagnostic Companies
Recent Deals & Alliances
The Global RNAi-Based Therapy Market 2008-2014
Analysis parameters
Market forecast 2008-2014
Global RNAi-Based Therapy Market in 2020
Drivers and market trends
Summary & Conclusions
Acknowledgements
Bibliography & Endnotes
List of Figures
Figure 1: siRNA - RISC mediated gene silencing
Figure 2: miRNA - RISC mediated gene silencing
Figure 3: High throughput RNAi screening for functional genomics and target validation
Figure 4: Rapid lead generation
Figure 5: ArteMice© RNAi model
Figure 6: RNAi therapeutics applications
Figure 7: Stages of pharmaceutical development
Figure 8: RNAi research: a timeline
Figure 9: RNAi-based therapeutics: defining therapeutic areas
Figure 10: Number of projects in the different stages of pharmaceutical development
Figure 11: Number of projects in each therapeutic area
Figure 12: Proportions of naked and targeted/vehicle assisted RNAi species
Figure 13: Delivery routes for RNAi therapeutics
Figure 14: Current approaches for cancer treatment
Figure 15: Potential RNAi approaches for cancer treatment
Figure 16: RONDEL delivery platform
Figure 17: In vivo efficacy studies with CALAA-01
Figure 18: Dicer substrate processing
Figure 19: Intratumoral siRNA delivery mediated with A) liposome and B) nanoparticles
Figure 20: RNAi NPX delivery platform
Figure 21: SNS-01 in mouse lung model
Figure 22: AtuPlex proprietary delivery system
Figure 23: SNALP delivery technology
Figure 24: Cequent's tkRNAi delivery system
Figure 25: LNA monomer structure
Figure 26: Polyplus transfection In-vivo-jetPEI system -RNAi delivery to the lung
Figure 27: Photochemical Internalization enhances siRNA's gene silencing effect
Figure 28: RNAi applications in CNS disorders
Figure 29: Medtronic's SynchroMed II implantable infusion pump
Figure 30: Alzet osmotic pump for brain infusion
Figure 31: Diffusion profile of pressure and diffusion delivery
Figure 32: Molecular schematic of ArmaGen's molecular Trojan horse
Figure 33: RNAi viral infectious disease targets
Figure 34: PARI Pharma's eFlow nebuliser
Figure 35: Tacere's shRNA construct to target HCV
Figure 36: Benitec's RNAi approach to HIV
Figure 37: Proof of concept Ebola siRNAs
Figure 38: RNAi ocular disease targets
Figure 39: RNAi applications in CV, metabolic & other disorders
Figure 40: miR-21 mechanism of action in myocardial infarction
Figure 41: ApoB SNALP preclinical data in mouse model
Figure 42: ApoB nanotransporter in mouse model
Figure 43: GeRP mechanism of delivery
Figure 44: NDT's siRNA delivery platform
Figure 45: Mechanism of action of siRNA HSP47 in liver cirrhosis
Figure 46: Challenges and opportunities for RNAi research
Figure 47: Safety issues
Figure 48: RNAi-based therapeutics: market drivers
List of Tables
Table 1: Antisense drugs in clinical development
Table 2: Pros and cons of RNAi silencing agents
Table 3: Leading RNAi diagnostic companies
Table 4: Novel non-coding RNA
Table 5: Diseases targeted by RNAi-based therapeutics
Table 6: RNAi and RNA therapeutic & diagnostic companies discussed in this report
Table 7: Leading companies evaluating RNAi therapies for cancer
Table 8: Academic institutions with an interest in RNAi based cancer research
Table 9: Potentially pro-oncogenic and tumor suppressor miRNAs
Table 10: Identification of key tumor suppressor miRNAs
Table 11: Leading companies evaluating RNAi-based therapies for CNS disorders
Table 12: Academic institutions with an interest in RNAi for the treatment CNS disorders
Table 13: Leading companies evaluating RNAi-based therapies for viral infectious diseases
Table 14: Academic institutions with an interest in RNAi for the treatment of viral infectious diseases
Table 15: Leading companies evaluating RNAi-based therapies for ocular diseases
Table 16: Academic institutions with an interest in RNAi for the treatment of ocular diseases
Table 17: Leading companies evaluating RNAi-based therapies for cardiovascular disease
Table 18: Academic institutions with an interest in RNAi for the treatment of cardiovascular disease, metabolic & other conditions
Table 19: Leading companies evaluating RNAi-based therapies for metabolic disorders
Table 20: Academic institutions with an interest in RNAi for the treatment of metabolic disorders
Table 21: Leading companies evaluating RNAi-based therapies for other conditions
Table 22: A seminal RNAi patents
Table 23: Summary of leading RNAi-based therapeutic companies
Table 24: Recent RNAi acquisitions & licensing deals
Table 25: Recent RNAi alliances
Table 26: RNAi-based therapies included in the market forecast
Table 27: Forecast of pipeline RNAi therapy products 2008-2014 (US$m)
Table 28: Forecast of pipeline RNAi therapy products 2015-2020 (US$m)
To order this report:
Biotechnology Industry: Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities
Check our Company Profile, SWOT and Revenue Analysis!
Contact: |
|
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article